Keywords cutaneous warts - dermatological life quality index - homeopathy - randomized controlled
trial
Introduction
Skin warts are benign tumors caused by infection of keratinocytes by human papilloma
virus (HPV), visible as well-defined hyperkeratotic protrusions.[1 ]
[2 ] These may adopt a variety of patterns depending on the anatomical location or morphology,
associated other skin diseases, on the causative agent, duration, immunologic status,
family history, and treatment history.[3 ]
[4 ] Warts affect approximately 10% of the population worldwide.[5 ] Viral warts are a global burden, with an average “disability weight” of 0.029 (weighting
factor that reflects severity of the disease on a scale from 0 [perfect health] to
1 [equivalent to death]).[6 ] Though rare in infancy and early childhood, overall prevalence is as high as 10
to 20% in school-going children, with a peak at 12 to 16 years.[7 ] The same scenario is found in the Indian population, where 46% of cases are in the
age group 14 to 20 years.[8 ] India, being a mostly tropical country, has a climate that favors viral infections
including warts. Some warts, especially plantar, are found to have a seasonal variation,
increasing during the winter months.[9 ]
[10 ]
“Wait and watch” is the preferred form of treatment for warts, as the rate of spontaneous
regression is high.[11 ]
[12 ] Besides, many other treatments are also available—home remedies (hot water,[13 ]
[14 ] garlic extract,[15 ]
[16 ] duct tape,[17 ] etc.), over-the-counter (OTC) therapies (salicylic acid[18 ]
[19 ]), and destructive treatment[20 ] (surgical[21 ]
[22 ] and chemical[23 ]). No single treatment is found to be fully effective.[24 ] Viral infection is not assumed to be the sole cause of warts in infected people.[25 ] This, in turn, supports the homeopathic philosophy that it is not just the virus/external
cause that produces disease but that some internal malady lies behind the production
of disease.[26 ] The removal of the end product of the disease by local means leaves the disease
lingering in the system and it recurs either in the same manner or in another form.
Viral warts are not the sole results of virus but remain merely as an external sign.
The internal causes refer to natural disposition and individuality of the patient.[27 ] Warts appear in different forms, shapes, sensations, discharges, and at different
sites according to the predominant “miasm” of the patient.[26 ] Though warts are the external manifestations, they represent the internal derangement
and play an important role in distinguishing between different cases of disease and
thus the appropriate remedy.[26 ]
There are studies[28 ]
[29 ]
[30 ] exploring the effects of various homeopathic medicines in warts. Successful treatment
and complete remission of warts with homeopathic medicines have been documented in
observational studies,[31 ]
[32 ] a case series,[33 ] and case reports.[34 ]
[35 ] In contrast to these findings, there are also several placebo-controlled, double-blind
trials[36 ]
[37 ]
[38 ]
[39 ]
[40 ] that have reported non-significant results. One reason for the discrepancy might
be that selection of trial medicines was from a pre-defined list, which does not fully
comply with the homeopathic principle of individualization. Reviews concluded that
there was no consistent evidence for the efficacy of homeopathy for warts, considering
the heterogeneity in the design of the trials.[41 ]
[42 ] A double-blind trial with pre-defined remedies has also been initiated in 2019 by
the Central Council for Research in Homoeopathy (CCRH).[43 ] With such scarcity of quality evidence, the treatment of warts remains a “gray area”
in homeopathy.
This double-blind, placebo-controlled, pilot trial aimed to assess differences between
individualized homeopathic (IH) medicines and placebos in the treatment of cutaneous
warts. Most importantly, it aimed to explore feasibility of a future larger-scale
trial, related to the issues of recruitment, randomization, treatment, assessment
of outcome measures, follow-up, and the time needed to collect and analyze data.
Methods
Trial Design
A double blind, randomized, placebo-controlled, two parallel arms, pilot clinical
trial was conducted at the Out-Patient Department-3 (OPD-3) of D.N. De Homoeopathic
Medical College and Hospital, West Bengal. The study protocol was approved by the
Institutional Ethical Committee (IEC) [Ref. No. DHC/Eth-45/2018/643/19, dated September
17, 2019] and was registered prospectively in the Clinical Trials Registry, India
[CTRI/2019/10/021659], prior to enrolment of the patients. It also had a secondary
identifier (Universal Trial Number) of U1111–1241–7340. The trial protocol and full
project report were submitted under a Short-Term Studentship in Homeopathy 2019 to
CCRH, identification number 190292 (https://ccrhscholarship.in/results/result-stsh-2019 ).
Participants
Inclusion criteria included adults aged between 18 and 65 years, of either sex, literate,
consenting to participate, and suffering from cutaneous warts (non-genital; 2020 ICD-10-CM
diagnosis code B07.9) for variable periods of time and not taking any other treatment
for those warts for at least 1 month. Patients already undergoing treatment for warts
were recruited only after having completely stopped that therapy and with a subsequent
wash-out phase of 1 month or more. Exclusion criteria consisted of patients with ano-genital
and genital warts, individuals diagnosed with unstable psychiatric illnesses or any
disease affecting quality of life (QoL), immuno-compromised state, pregnant women
and lactating mothers, substance abuse and/or dependence, or undergoing homeopathic
treatment for any chronic disease within the last 6 months.
Intervention
Patients were randomized into two parallel arms:
Verum: Indicated homeopathic medicines in centesimal potencies, as decided appropriate
to the case or condition, were administered. In centesimal scale, each dose consisted
of six to eight globules (no. 10) of cane sugar, medicated with a single drop of the
indicated medicine (preserved in 90% v/v ethanol), taken orally on a clean tongue
and with empty stomach; dosage and repetition depending upon the individual requirement
of the cases. Duration of therapy was 3 months. Final selection of the single individualized
medicine and dosage was in accordance with the standard homeopathic guidelines and
agreement among three homeopaths. The prescriptions on follow-up visits were generated
as per relevant homeopathic principles and were recorded in follow-up sheets. One
of the prescribers possessed a Master's degree in homeopathy, with more than 15 years
of experience of teaching and practicing classical homeopathy; the other two prescribers
were a postgraduate trainee and an intern at D.N. De Homoeopathic Medical College
and Hospital, West Bengal. All the homeopaths were affiliated with state councils.
Comparator: Placebos, visually indistinguishable from verum, were administered over
a period of 3 months. Each dose of placebo consisted of six to eight globules (no.
20) of cane sugar, moistened with rectified spirit, to be taken orally on a clean
tongue and with empty stomach; dosage and repetition depending upon the individual
requirement of the cases. Participants in the control arm were assessed by the three
homeopaths in the same way as was done in the experimental arm. “Placebo prescription”
was similar to that for patients receiving an actual medicine and was dispensed by
the blinded pharmacist from identical-looking coded vials as per the random number
chart. Thus “placebo prescription” seemed similar to verum and was blinded to the
patients, prescribing doctors and outcome assessors. Irrespective of codes, provision
was kept to prescribe different “acute medicines” (rescue remedies) based on “acute
totality” to counter any adverse or serious adverse events as per homeopathic principles.
The homoeopathic medicines and placebos were both provided by Hahnemann Publishing
Company Private Limited (HAPCO; 165, Bipin Bihari Ganguly Street, Baithakkhana, Bowbazar,
Kolkata 700012, West Bengal, India)—a good manufacturing practice (GMP)-certified
pharmaceutical company. Both medicines and placebos were re-packed in identical glass
bottles and labeled with code, name of medicine, potency, and were dispensed according
to the randomization list.
General Management
To prevent spread of the virus, patients were asked to maintain basic personal hygiene
measures, with thorough hand washing after touching any wart, avoiding brushing, combing,
shaving, or picking the areas where warts were present.
Outcomes
Primary: The number of the warts was counted, and the size of each wart was measured by a
millimeter (mm) scale on its longest diameter. Each patient was followed up every
month for 3 months.
Secondary: Dermatological Life Quality Index (DLQI)[44 ] is a valid generic questionnaire comprising 10 items provided with a Likert-type
scale (3, very much; 2, a lot; 1, a little; and 0, not at all or not relevant) for
assessing dermatological conditions in adults. Total score is calculated by summing
up the scores for each of the 10 questions. Maximum score is 30; higher scores represent
worse QoL. The questions are also classified into six domains: symptoms and feelings
(items 1 and 2); daily activities (items 3 and 4); leisure (items 5 and 6), and personal
relationships (items 8 and 9); work and school (item 7); and treatment (item 10).
Question number 7 is rated as either “3” (prevented work or studying) or “0” (no,
or not relevant). English and Bengali versions of the DLQI questionnaire are shown
in [Supplementary Files 1 ] and [2 ], available online only.
We considered a priori a recruitment rate of above 50% and retention rate of above 80% as satisfactory and
as a specific indication for pursuing an adequately powered definitive trial in future.
Sample Size
There was no paper reporting relevant data for effect size (standardized mean difference)
and sample size calculation. Accounting for an expected attrition rate of up to 10%,
and to detect a statistically significant difference between two independent means
of the number of warts (primary outcome measure) after 3 months of intervention through
unpaired t -test, a study with 2 × 70 patients would give 80% power based on a two-sided significance
level of 5%. However, keeping in mind the stipulated timeframe of 6 months for the
entire project (approval in October 2019, conclusion in March 2020, and final report
submission by April 2020; available at: https://ccrhscholarship.in/ ), the exploratory nature of the pilot trial and feasibility issues, we aimed to achieve
60 patients (2 × 30), resulting in a compromised power of up to 60.4%, and warranting
cautious extrapolation and interpretation of the findings.
Randomization
The randomization chart was generated using StatTrek random number generator (https://stattrek.com/statistics/random-number-generator.aspx ) and patients were allocated to either the verum or the comparator group. The chart
was prepared by an independent third party using restricted six blocks of size 10
(6 × 10 = 60) to maintain 1:1 ratio. Thus, an equal number of patients was randomized
to the verum and to the control group.
Blinding
A double-blinding method was adopted: the patients, the treating physicians, the outcome
assessors, and the data-entry operator all remained blinded.
Allocation Concealment
It was maintained by identically coded containers having alike vials coded as “1”
or “2” indicating either of medicine or placebo, assigned randomly and confidentially
by a third party. The coded randomization chart was made available to the blinded
pharmacist to provide medicines accordingly from the coded vials. Confidentiality
was maintained strictly until the end of the trial. Randomization codes were broken
at the end of the trial after the dataset was frozen.
Statistical Methods
Every included patient was entered for the final analyses—i.e., intention-to-treat
(ITT) approach. Missing values were replaced by last observation carried forward.
Non-parametric tests were used as inferential statistics. Dependent observations of
continuous outcomes at baseline and at different points of time were compared using
Friedman tests. Group differences were tested at baseline, every month, and up to
3 months by Mann-Whitney U tests. p -Values were set at less than 0.05, two-tailed, as statistically significant. A common
effect size statistic, r , was calculated from the Mann-Whitney U test, as proposed by Cohen,[45 ] by dividing the Z -value by the square root of the total number of observations (N
obs ): that is, r = Z /√(Nobs ).[46 ] This effect size r varies from 0 to 1, where 0.10 to <0.30 is considered as small; 0.30 to <0.50 as
medium; and ≥0.50 as large.[47 ] All analyses were performed in SPSS IBM v.20 for Windows.
Ethical Considerations
In this project, neither a new drug was experimented on nor any new treatment protocol
adopted. Intervention was in strict adherence to IH principles. Prior to enrolment,
each patient was provided with an information sheet in the local language, Bengali,
detailing the objectives, methods, risks and benefits of participating, and confidentiality
issues. Subsequent to that, written informed consent was obtained. Approval was obtained
from the Institutional Ethics Committee (IEC) prior to initiation. The study was performed
under the constant supervision of the IEC. We had prospective registration of the
trial protocol in a trial registry (http://ctri.nic.in/Clinicaltrials/showallp.php?mid1 =37368&EncHid = &userName = CTRI/2019/10/021659), thus making it transparent in conduct
and reporting. The protocol conformed to the Declaration of Helsinki for ethical conduct
of clinical trials involving human participants.
Trial Reporting
Reporting of the trial was in compliance with the Consolidated Standards for Reporting
Trials (CONSORT) extension statement for randomized pilot trials[48 ] and with the Reporting Data on Homeopathic Treatment (RedHot)[49 ] guidelines ([Supplementary Files 3 ] and [4 ], available online only: CONSORT and RedHot checklists).
Reporting of Adverse Events
The investigators had instructed the patients to report any harm, unexpected effect,
serious adverse event, or undue aggravation—either directly in the OPD or over the
telephone during the trial.
Results
Participant Flow
Eighty-nine patients with warts were screened as per specified inclusion and exclusion
criteria; 60 met the eligibility criteria; 29 were excluded because of various reasons
specified in the flow diagram ([Fig. 1 ]). The patients were randomized to receive either of IH or identical-looking placebo.
Following intervention for 3 months, seven patients (IH, 3; placebo, 4) dropped out
from the study. The reasons were change of residence for two patients and dissatisfaction
with treatment as reported by one; two did not specify any reason and two could not
be contacted ([Fig. 1 ]: Study flow diagram).
Fig. 1 Study flow diagram. ITT, intention to treat.
Recruitment
The enrolment period spanned 4 months, from October 2019 until January 2020 inclusive.
Follow-up of the last enrolled patient was completed in March 2020. Total study duration
was 6 months.
Baseline Data
Ten socio-demographic and clinical features were studied at baseline to test for any
statistically significant differences between the two groups, by using Chi-square
tests and t -tests respectively for categorical variables (sex; residence; occupation; socio-economic
status; shape, surface, color, and site of warts) and continuous variables (age; body
mass index). The majority of warts were distributed on the face (n = 23; 38.3%) and extremities (n = 17; 31.6%), either rough (n = 26; 43.3%) or smooth (n = 27; 45%), mostly black in color (n = 27; 45%), and single in number (n = 31; 51.7%). There were no significant differences in distribution of any of these
variables, thus ensuring comparability between the groups ([Table 1 ]).
Table 1
Comparison of socio-demographic characteristics between two groups at baseline (N = 60)
Features
Verum group (n = 30)
Placebo group (n = 30)
χ
2 value or t
58 score
p -Value
Age (years)[a ]
40.4 ± 16.1
40.5 ± 13.6
0.035
0.972
Body mass index[a ]
24.0 ± 4.6
23.2 ± 5.3
−0.582
0.563
Sex[b ]
• Male
• Female
17 (56.7)
13 (43.3)
10 (33.3)
20 (66.7)
2.424
0.119
Residence[b ]
• Rural
• Semiurban
• Urban
5 (16.7)
1 (3.3)
24 (80)
6 (20)
2 (6.7)
22 (73.3)
0.022
0.989
Occupation[b ]
• Service
• Business
• Farming
• Dependent
1 (3.3)
9 (30)
3 (10)
17 (56.7)
3 (10)
3 (10)
3 (10)
21 (70)
2.737
0.434
Socio-economic status[b ]
• Poor or low
• Middle and upper
5 (16.7)
25 (83.3)
7 (23.3)
23 (76.7)
0.104
0.747
Shape of warts[b ]
• Round or oval
• Irregular
• Filiform
• Others
21 (70)
2 (6.7)
2 (6.7)
5 (16.7)
21 (70)
2 (6.7)
1 (3.3)
6 (20)
0.274
0.965
Surface of warts[b ]
• Rough
• Smooth
• Others
16 (53.3)
11 (36.7)
3 (10)
10 (33.3)
15 (50)
5 (16.7)
1.433
0.488
Color of warts[b ]
• Black
• Brown
• Gray
• Skin colored
• Others
13 (43.3)
9 (30)
3 (10)
3 (10)
2 (6.7)
14 (46.7)
9 (30)
3 (10)
2 (6.7)
2 (6.7)
0.472
0.976
Site of warts[b ]
• Neck
• Chest, abdomen, back
• Arms, hands, and fingers
• Face
• Scalp
• Thighs, legs, foot
6 (20)
2 (6.7)
10 (33.3)
6 (20)
5 (16.7)
1 (3.3)
3 (10)
1 (3.3)
7 (23.3)
17 (56.7)
1 (3.3)
1 (3.3)
7.028
0.218
a Continuous data presented as means ± standard deviations and unpaired t -test applied; t
58 : t score at 58 degrees of freedom.
b Categorical data presented as absolute values (percentages) and chi-square test with
Yates' correction applied; p -Value less than 0.05 two-tailed was considered as statistically significant.
Numbers Analyzed
Out of the 30 enrolled in each group, outcomes data were complete for 27 and 26 patients
in the IH and placebo groups respectively. ITT analysis included all the randomized
patients (n = 60).
Feasibility Issues
Recruitment rate was found to be 67.4%. The major reasons for exclusion were illiteracy
(48%) and declining to consent (20%). The retention rate of 88% in this trial was
acceptable. There were no obstacles faced in relation to randomization, blinding,
outcome assessment and follow-up of any patient.
Outcomes and Estimation
Number and size of warts: Intra-group changes in the number of warts after 3 months were significantly greater
(p < 0.01, Friedman tests) in the IH group than in the placebo group (p = 0.666). However, the inter-group differences were statistically non-significant
(all p > 0.05; Mann-Whitney U tests), with small effect sizes (IH median [inter-quartile range; IQR] 1 [1, 3] vs.
placebo 1 [1, 2]; Mann-Whitney U = 429, Wilcoxon W = 894, Z = [−0.330], p = 0.741, r = 0.08). Intra-group changes in the size of warts after 3 months were again significantly
greater (p < 0.001, Friedman tests) in the IH group than placebo group (p = 0.014), but the inter-group differences were statistically non-significant (p > 0.05, Mann-Whitney U tests), with small effect sizes (IH median [IQR] 5.6 [2.6, 40.2] vs. placebo 6.3
[0.8, 16.7]; Mann-Whitney U = 406, Wilcoxon W = 871, Z = [−0.652], p = 0.515, r = 0.169) ([Table 2 ]).
DLQI score: Except for the domains of leisure and personal relations, intra-group changes with
time showed significant improvement in each domain, and in total DLQI, in both the
verum and placebo groups. The inter-group differences in all the domains (symptoms
and feelings, p = 0.903; daily activity, p = 0.760; leisure, p = 0.795; work and school, p = 0.643; personal relations, p = 1.000; treatment, p = 0.587), and in total DLQI score (p = 0.935), were statistically non-significant ([Table 3 ]).
Table 2
Comparison of the numbers and sizes of warts at baseline and every month up to 3 months
(N = 60; Verum group, 30; Placebo group, 30)
Primary outcomes
Baseline:
Median (IQR)
After 1 month:
Median (IQR)
After 2 months: Median (IQR)
After 3 months: Median (IQR)
χ
2 at df = 3
p -Valueb
Number of warts
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W test
Z-test
p -Valuea
Eta-square (η
2 )
Effect size (r )
1.5 (1, 3)
1 (1, 2)
382.5
847.5
−1.099
0.272
–
–
1.5 (1, 3)
1 (1, 2)
400.0
865.0
−0.807
0.420
0.009
0.192
1 (1, 3)
1 (1, 2)
412.0
877.0
−0.605
0.545
0.005
0.145
1 (1, 3)
1 (1, 2)
429.0
894.0
−0.330
0.741
0.002
0.08
12.000
1.571
0.007**
0.666
Size of warts
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z-test
p -Valuea
Eta-square (η
2 )
Effect size (r )
19.6 (6.5, 52.9)
12.6 (2.6, 21.9)
348.0
813.0
−1.510
0.131
–
–
9.4 (3.7, 47.9)
11.8 (2.6, 21.9)
401.5
866.5
−0.718
0.473
0.009
0.186
6.7 (3.1, 40.2)
6.7 (0.8, 20.0)
383.0
848.0
−0.992
0.321
0.016
0.258
5.6 (2.6, 40.2)
6.3 (0.8, 16.7)
406.0
871.0
−0.652
0.515
0.007
0.169
24.487
10.660
<0.001***
0.014*
Abbreviation: IQR, inter-quartile range.
Note: p < 0.05 considered as statistically significant.
*
p <0.05. **
p < 0.01. ***
p < 0.001.
p -Value(a) reflects inter-group differences detected by Mann Whitney U tests, whereas p -value(b) represents intra-group changes detected by Friedman test.
Table 3
Comparison of the DLQI measure at baseline and every month up to 3 months
(N = 60; Verum group, 30; Placebo group, 30)
Outcome measures
Baseline:
Median (IQR)
After 1 month:
Median (IQR)
After 2 months: Median (IQR)
After 3 months: Median (IQR)
χ
2 at df = 3
p -Valueb
DLQI: Symptoms and feelings
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z -test
p -Valuea
Eta-square (η
2 )
Effect size (r )
3 (2, 4)
2 (2, 3)
367.5
832.5
−1.257
0.209
–
–
2.5 (1, 3.2)
2 (2, 3)
383.0
848.0
−1.028
0.304
0.016
0.258
2 (1, 3)
2 (1, 3)
427.5
892.5
−0.343
0.731
0.002
0.086
2 (1, 3)
2 (1, 3)
442.0
907.0
−0.122
0.903
0
0.031
23.762
15.361
<0.001***
0.002**
DLQI: Daily activity
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z -test
p -Valuea
Eta-square (η
2 )
Effect size (r )
1 (1, 2.2)
1 (0, 2)
392.0
857.0
−0.888
0.374
–
–
1 (1, 2)
1 (0, 1.2)
338.5
803.5
−1.727
0.084
0.045
0.436
1 (0, 2)
1 (0, 2)
421.0
886.0
−0.449
0.653
0.003
0.111
1 (0, 2)
1 (0, 2)
430.5
895.5
−0.306
0.760
0.001
0.074
18.360
10.763
<0.001***
0.013**
DLQI: Leisure
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z- test
p -Valuea
Eta-square (η
2 )
Effect size (r )
1 (0, 2)
1 (0, 1.2)
447.5
912.5
−0.039
0.969
–
–
1 (0, 2)
1 (0, 1.2)
384.5
849.5
−1.030
0.303
0.016
0.252
1 (0, 2)
1 (0, 2)
419.5
884.5
−0.482
0.630
0.003
0.117
1 (0, 2)
1 (0, 2)
433.5
898.5
−0.260
0.795
0.001
0.063
1.310
7.062
0.727
0.070
DLQI: Work and school
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z -test
p -Valuea
Eta-square (η
2 )
Effect size (r )
0 (0, 3)
0 (0, 3)
450.0
915.0
0.000
1.000
–
–
0 (0, 0)
0 (0, 0.7)
420.0
885.0
−0.640
0.522
0.003
0.115
0 (0, 0)
0 (0, 0)
420.0
885.0
−0.853
0.393
0.003
0.115
0 (0, 0)
0 (0, 0)
435.0
900.0
−0.463
0.643
0.001
0.057
17.690
13.846
0.001**
0.003**
DLQI: Personal relations
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z -test
p -Valuea
Eta-square (η
2 )
Effect size (r )
1 (0, 1.2)
0 (0, 1)
331.5
796.5
−1.889
0.059
–
–
0 (0, 1)
0 (0, 1)
440.5
905.5
−0.156
0.876
0
0.036
0 (0, 1)
0 (0, 1)
433.0
898.0
−0.284
0.777
0.001
0.065
0 (0, 1)
0 (0, 1)
450.0
915.0
0.000
1.000
0
0
7.800
4.500
0.050
0.212
DLQI: Treatment
• Veum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z -test
p -Valuea
Eta-square (η
2 )
Effect size (r )
1 (0, 1)
1 (0, 1)
393.0
858.0
−0.913
0.361
–
–
0 (0, 1)
0 (0, 1)
435.0
900.0
−0.263
0.792
0.001
0.057
0 (0, 1)
0 (0, 1)
415.0
880.0
−0.617
0.537
0.004
0.134
0 (0, 1)
0 (0, 1)
420.0
885.0
−0.543
0.587
0.003
0.115
30.081
15.000
<0.001***
0.002**
DLQI: Total score
• Verum group
• Placebo group
Mann-Whitney U test
Wilcoxon W-test
Z -test
p -Valuea
Eta-square (η
2 )
Effect size (r )
8.5 (5, 12)
7 (4.5, 9)
370.0
835.0
−1.187
0.235
–
–
6 (4, 9)
5.5 (3, 8)
388.0
853.0
−0.921
0.357
0.014
0.238
4.5 (2.7, 8)
5 (3, 8)
444.5
909.5
−0.082
0.935
0
0.021
4.5 (2, 6.2)
4.5 (2.5, 8)
444.5
909.5
−0.082
0.935
0
0.021
33.000
35.082
<0.001***
<0.001***
Abbreviations: DLQI, dermatological life quality index; IQR, inter-quartile range;
p < 0.05 considered as statistically significant.
*
p < 0.05. **
p < 0.01. ***
p < 0.001.
p -Value(a) reflects inter-group differences detected by Mann Whitney U tests, whereas p -value(b) represents intra-group changes detected by Friedman test.
Medicines Used
The most frequently prescribed medicines were Thuja occidentalis (28.3%), Natrum muraticum (10%), Sulphur (8.3%), Dulcamara and Nitricum acidum (6.7% each), Antimonium crudum and Causticum (5% each), Mercurius solubilis and Calcarea carbonicum (3.3% each)—[Supplementary Files 5 ], available online only. As per the protocol, medicines were prescribed in centesimal
potencies only. There were no significant inter-group differences in the frequency
of prescription of the indicated remedies (all p > 0.05) ([Table 4 ]).
Table 4
Alphabetical list of medicines prescribed in the two groups at baseline
Name of the medicine
Total (N = 60); n (%)
Verum (n = 30);
n (%)
Placebo (n = 30);
n (%)
Chi-square
p -Value[a ]
1. Antimonium crudum
3 (5)
–
3 (10)
–
2. Arsenicum album
1 (1.7)
–
1 (3.3)
–
3. Calcarea carbonica
2 (3.3)
2 (6.7)
–
4. Calcarea phosphorica
1 (1.7)
1 (3.3)
–
5. Causticum
3 (5)
2 (6.7)
1 (3.3)
0
1.000
6. Dulcamara
4 (6.7)
3 (10)
1 (3.3)
0.268
0.605
7. Graphites
1 (1.7)
–
1 (3.3)
–
8. Lachesis mutus
1 (1.7)
–
1 (3.3)
–
9. Lycopodium clavatum
1 (1.7)
–
1 (3.3)
–
10. Medorrhinum
1 (1.7)
1 (3.3)
–
11. Mercurius solubilis
2 (3.3)
2 (6.7)
–
12. Mezereum
1 (1.7)
1 (3.3)
–
13. Natrum carbonicum
1 (1.7)
1 (3.3)
–
14. Natrum muriaticum
6 (10)
1 (3.3)
5 (16.7)
1.667
0.197
15. Natrum sulphuricum
1 (1.7)
–
1 (3.3)
–
16. Nitricum acidum
4 (6.7)
3 (10)
1 (3.3)
0.268
0.605
17. Nux vomica
1 (1.7)
–
1 (3.3)
–
18. Pulsatilla nigricans
1 (1.7)
1 (3.3)
–
19. Rhus toxicodendron
1 (1.7)
–
1 (3.3)
–
20. Ruta graveolens
1 (1.7)
1 (3.3)
–
21. Staphysagria
1 (1.7)
1 (3.3)
–
22. Sulphur
5 (8.3)
3 (10)
2 (6.7)
0
1.000
23. Thuja occidentalis
17 (28.3)
7 (23.3)
10 (33.3)
0.328
0.567
a Pearson's Chi-square test with Yates' correction, p < 0.05 considered as statistically significant.
Adverse Events
No harms, homeopathic aggravations or serious adverse events were reported by any
of the patients in the study period of 3 months.
Discussion
A double-blind, pilot, RCT was performed on 60 patients suffering from cutaneous warts.
The patients were treated with either IH or indistinguishable placebo. Intra-group
changes were greater in IH than placebo, but inter-group differences were non-significant
statistically. The results of our trial inform the feasibility of an adequately powered
and more definitive trial in future.
The most common location of warts found in our trial was the face (38.3%), and the
second most common site was the extremities (31.6%), especially the arms, a finding
similar to that of Ghadgepatil et al[50 ] in Pune, India. In a prevalence study from Pondicherry, India,[8 ] single-site involvement for warts in adults was common. The finding of our study
was similar—out of the total 60 patients, 31 complained of single warts and 29 of
multiple warts. Villeda et al[51 ] compared Thuja occidentalis with placebo in children, and Labrecque et al[39 ] compared IH with placebo in adults. The effect sizes of all these studies were small
and statistically non-significant. Whilst Manchanda et al[40 ] reported 63.3% improvement in the verum group, Schultz[38 ] found no clinically significant results with homeopathic treatment. One observational
study on 100 patients spanning all age groups reported promising effects of Dulcamara 1,000cH, Natrum muriaticum 1,000cH and Thuja occidentalis 1,000cH by shortening the duration of ailment.[31 ] A similar study in the same setting on 200 patients suffering from warts revealed
encouraging results from the use of those same three medicines.[32 ]
There have been no studies exclusively in adults with warts, and none of the previous
RCTs adhered fully to the principles of IH because they restricted the prescription
choice within a specified number of medicines. Thus, our pilot study aimed at rectifying
the perceived deficiency of existing trials by informing a future investigation. All
the studies, except one, analyzed the results only on the basis of objective symptoms.
One trial, which included subjective symptoms by using a questionnaire about satisfaction
with the treatment, found that even if the size of the warts was not reducing significantly,
the patients were satisfied with the mode of treatment, as the intervention was not
only safer than destructive processes but it also gave psychological support to the
participants.[38 ] In our study also, we considered both the objective measures (size and number of
warts) and the subjective measure (DLQI scale) for the interpretation of the results.
There were significant improvements in DLQI scores within both the groups, but without
any statistically significant inter-group differences.
Being an RCT with 1:1 randomization, every enrolled patient had an equal chance of
being allocated to either of the groups, thereby minimizing the chances of selection
bias. Warts not being an emergency condition, ethical concerns were relatively small.
For the first time, the study was done exclusively in adults because warts in adults
are more resistant to treatment and are less amenable to spontaneous regression in
comparison to children.[11 ]
[12 ] Although the recruitment rate was not adequate and needs improvement, retention
rate for this pilot trial was quite promising, thereby ensuring feasibility of a more
definitive trial in future. Duration of the study was 3 months only; thus, there were
fewer chances that the lesions might develop complications or become malignant.
Owing to small sample size, our trial was underpowered, thus preventing the findings
from being extrapolated[52 ]; nevertheless, the trial had not primarily aimed to enable such interpretation.
Patients were enrolled only on the basis of clinical diagnosis; no histological examination,
immunohistochemistry, or polymerase chain reaction (PCR) for HPV DNA could be used
as confirmatory tools for diagnosis. Therefore, which particular type(s) of HPV responded
best to treatment could not be explored in this trial.
Skin complaints, especially warts, seem an area where homeopathy can have favorable
effects, especially in the context of non-invasive treatment options and with standard
therapies having limited efficacy. Future studies with a suitably large sample size,
along with PCR for HPV DNA analysis, can bring about more valid, interpretable, as
well as more generalizable results.
Conclusion
As regards efficacy of treatment, the result of the pilot study was inconclusive,
with a non-significant trend in favor of IH compared with placebo. Importantly, however,
it paves the way for a future, adequately powered, definitive trial that could enable
detection of a clinically meaningful difference.
